Methods and products for transfecting cells

Patent metadata

Field	Value
Publication number	US-10829738-B2
Application number	US-202016857894-A
Country	US
Kind code	B2
Filing date	Apr 24, 2020
Priority date	Dec 5, 2011
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

First claim

What is claimed is:

1. A method for producing a gene-edited cell, comprising:
(a) providing a cell comprising a target DNA sequence, wherein the cell is a human cell;
(b) culturing the cell; and
(c) transfecting the cell with a plurality of synthetic RNA molecules, wherein the synthetic RNA molecules include:
i. a first synthetic RNA molecule encoding a first fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease; and
ii. a second synthetic RNA molecule encoding a second fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease;
wherein:
the first fusion protein and the second fusion protein are independently a transcription activator-like effector nuclease (TALEN); and
the transfecting results in the cell expressing the first fusion protein and the second fusion protein to result in a double-strand break in the target DNA sequence.

2. The method of claim 1 , wherein the first synthetic RNA molecule and the second synthetic RNA molecule are independently synthesized by in vitro transcription from a DNA template, wherein the DNA template encodes a plurality of monomer repeats, wherein each monomer repeat comprises a repeat variable domain (RVD), and wherein the RVDs are selected to target a sequence within the target DNA sequence.

3. The method of claim 1 , further comprising contacting the cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

4. The method of claim 1 , further comprising contacting the cell with a medium.

5. The method of claim 4 , wherein the medium is substantially free of immunosuppressants.

6. The method of claim 1 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule comprise at least one member of the group consisting of: a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, and a 5-methylcytidine residue.

7. The method of claim 6 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule comprise uridine residues, and wherein between 20% and 100% of the uridine residues are 5-hydroxyuridine residues.

8. The method of claim 1 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule further comprise one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

9. A method for producing a gene-edited cell comprising an inserted DNA sequence, comprising:
(a) providing a cell comprising a target DNA sequence, wherein the cell is a human cell;
(b) culturing the cell;
(c) transfecting the cell with a plurality of synthetic RNA molecules, wherein the synthetic RNA molecules include:
i. a first synthetic RNA molecule encoding a first fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease; and
ii. a second synthetic RNA molecule encoding a second fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease;

wherein the first fusion protein and the second fusion protein are independently a transcription activator-like effector nuclease (TALEN); and wherein the transfecting results in the cell expressing the first fusion protein and the second fusion protein to result in a double-strand break in the target DNA sequence; and
(d) transfecting the cell with a DNA repair template comprising a sequence for insertion and one or more regions of homology to the DNA of the cell, wherein the one or more regions of homology comprise regions upstream and/or downstream of the double-strand break, to result in insertion of the sequence in the region of the double-strand break.

10. The method of claim 9 , wherein the first synthetic RNA molecule and the second synthetic RNA molecule are independently synthesized by in vitro transcription from a DNA template, wherein the DNA template encodes a plurality of monomer repeats, wherein each monomer repeat comprises a repeat variable domain (RVD), and wherein the RVDs are selected to target a sequence within the target DNA sequence.

11. The method of claim 9 , further comprising contacting the cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

12. The method of claim 9 , further comprising contacting the cell with a medium.

13. The method of claim 12 , wherein the medium is substantially free of immunosuppressants.

14. The method of claim 9 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule comprise at least one member of the group consisting of: a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, and a 5-methylcytidine residue.

15. The method of claim 14 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule comprise uridine residues, and wherein between 20% and 100% of the uridine residues are 5-hydroxyuridine residues.

16. The method of claim 9 , wherein the first synthetic RNA molecule, the second synthetic RNA molecule, or both the first synthetic RNA molecule and the second synthetic RNA molecule further comprise one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• H10F19/80

  Encapsulations or containers for integrated devices, or assemblies of multiple devices, having photovoltaic cells · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C12N15/907 Primary

  in mammalian cells · CPC title

• C12N15/87 Primary

  Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title